Select Page
FDA Accepts Axsome Therapeutics NDA for AXS-07

FDA Accepts Axsome Therapeutics NDA for AXS-07

Biopharmaceutical company Axsome Therapeutics, known for developing innovative therapies for central nervous system (CNS) disorders, announced that the FDA (Food and Drug Administration) has accepted their New Drug Application (NDA) for AXS-07 for acute migraine...
Soin Therapeutics receives FDA Orphan Drug Status Grant

Soin Therapeutics receives FDA Orphan Drug Status Grant

The US FDA (Food and Drug Administration) has granted Ohio-based pharmaceutical company Soin Therapeutics orphan drug status for low dose naltrexone (LDN) for the treatment of complex regional pain syndrome (CRPS). Complex Regional Pain Syndrome is characterized by...
78 Million People With Dementia by 2030, WHO Predicts

78 Million People With Dementia by 2030, WHO Predicts

Dubbed a global health concern, The WHO (World Health Organization) has projected that the number of people living with dementia will increase to 78 million by the year 2030 and will cost the global economy $1.3 trillion p/a. Currently, there are over 55 million...